Related references
Note: Only part of the references are listed.Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
Asher Kornbluth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-alpha Inhibitor Therapy
Jeannina A. Smith et al.
DRUGS (2009)
The European (ECCO) Consensus on infection in IBD: what does it change for the clinician?
Jean-Francois Rahier et al.
GUT (2009)
Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease
Alain M. Schoepfer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab
Keisuke Ojiro et al.
JOURNAL OF GASTROENTEROLOGY (2008)
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
Robert S. Walls
LANCET INFECTIOUS DISEASES (2008)
American Gastroenterological Association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2006)
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
W Yeo et al.
HEPATOLOGY (2006)
Reactivation of latent granulomatous infections by infliximab
RS Wallis et al.
CLINICAL INFECTIOUS DISEASES (2005)
Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-α activity
GS Deepe
CLINICAL INFECTIOUS DISEASES (2005)
High Incidence of Anergy in Inflammatory Bowel Disease Patients Limits the Usefulness of PPD Screening Before Infliximab Therapy
William S. Mow et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients:: need for primary prophylaxis
M Esteve et al.
GUT (2004)
AGA technical review on perianal Crohn's disease
WJ Sandborn et al.
GASTROENTEROLOGY (2003)
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
JH Lee et al.
ARTHRITIS AND RHEUMATISM (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
